IL18 and COVID-19: Another potential candidate for IL-18-blocking therapy is the severe cytokine storm syndrome (Behrens, 2024) [79] seen in conditions such as patients undergoing CAR T therapy (Lichtenstein et al., 2021) (Diorio et al., 2022) [104,105] and in severe cases of COVID-19 (Sefik et al., 2022) [86].